# US 2016/0354374 A1 · Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354374 A1
- Document ID: US20160354374A1
- Status: Published application
- Kind: A1
- Application number: 15/241,232
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2013-12-20
- Assignees: Signal Pharmaceuticals, LLC
- Applicants: Signal Pharmaceuticals, LLC
- Inventors: Patrick Papa; Brian Edwin Cathers; Andrew Antony CALABRESE; Brandon Wade WHITEFIELD; Brydon BENNETT; Daniel CASHION; Deborah MORTENSEN; Dehua HUANG; Eduardo TORRES; Jason PARNES; John SAPIENZA; Joshua HANSEN; Katerina LEFTHERIS; Matthew CORREA; Maria Mercedes DELGADO; Raj K. RAHEJA; Sogole BAHMANYAR; Sayee HEGDE; Stephen NORRIS; Veronique PLANTEVIN-KRENITSKY
- Web page: https://patentgrep.com/patent/US20160354374A1

## CPC

- C07D 239/48: Two nitrogen atoms
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

## Claims

### Claim 1

A method for the treatment or prevention of PKC-theta mediated disorder comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof,
wherein:
X is CN or CF3;
L is (C1-4 alkyl);
R1 is substituted or unsubstituted heteroaryl; and
R2 is substituted or unsubstituted cycloalkyl,
wherein the PKC-theta mediated disorder is graft-versus-host disease, organ transplant rejection, psoriasis, Duchenne muscular dystrophy, rheumatoid arthritis, insulin resistance, myasthenia gravis, multiple sclerosis, colitis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, Sjogren syndrome, asthma, or lupus.

### Claim 2 (depends on 1)

The method of claim 1, wherein X is CN.

### Claim 3 (depends on 1)

The method of claim 1, wherein X is CF3.

### Claim 4 (depends on 1)

The method of claim 1, wherein L is CH2, CH2CH2 or CH2CH2CH2.

### Claim 5 (depends on 1)

The method of claim 1, wherein R1 is a substituted or unsubstituted pyridyl, pyridyl-1-oxide, or pyrimidyl.

### Claim 6 (depends on 5)

The method of claim 5, wherein R1 is substituted with one or more halogen, —OR3, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted aryl, wherein each R3 is independently H, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted aryl.

### Claim 7 (depends on 5)

The method of claim 5, wherein R1 is substituted with one or more F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, phenyl, naphthyl, —CH2F, —CHF2, —CF3, —CHFCH3, —CF2CH3, —C(CH3)2F, —OCH3, —OCH2F, —OCHF2, —OCF3, —OCH2CH3, —OCH2CH2F, —OCH2CHF2, —OCH2CF3, —OCH2CH(CH3)F, —OCH2C(CH3)2F, —OCH2C(CH3)F2, —OCH2CH2CF3, or —O-phenyl, wherein each phenyl is optionally substituted with halogen or substituted or unsubstituted C1-4 alkyl.

### Claim 8 (depends on 5)

The method of claim 5, wherein R1 is substituted with one or more F, Cl, methyl, ethyl, isopropyl, phenyl, —CF3, —CF2CH3, —C(CH3)2F, —OCH3, —OCH2CH3, —OCH2CF3, —OCH2CH2F, —OCH2CHF2, —OCH2C(CH3)F2, —OCH2CH2CF3, or —O-phenyl, wherein each phenyl is optionally substituted with F or methyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein R1 is a substituted or unsubstituted indolyl, indolinonyl, benzoxazolyl, pyrrolopyridyl, indazolyl, benzimidazolyl, dihydrobenzimidazolonyl, or quinolyl.

### Claim 10 (depends on 9)

The method of claim 9, wherein R1 is substituted with one or more halogen, CN, —OR3, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted aryl, wherein each R3 is independently H, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted aryl.

### Claim 11 (depends on 9)

The method of claim 9, wherein R1 is substituted with one or more F, Cl, CN, methyl, ethyl, —CH2SO2NHCH3, —OH, —OCH3, or OCF3.

### Claim 12 (depends on 1)

The method of claim 1, wherein R1 is a substituted or unsubstituted furanyl, pyrrolyl, thiophenyl, oxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, or triazolyl.

### Claim 13 (depends on 12)

The method of claim 12, wherein R1 is substituted with one or more halogen, CN, —OR3, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted aryl, wherein each R3 is independently H, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted aryl.

### Claim 14 (depends on 12)

The method of claim 12, wherein R1 is substituted with one or more CN, methyl, ethyl, —CF3, or —CH2OCH3.

### Claim 15 (depends on 1)

The method of claim 1, wherein R2 is substituted or unsubstituted C3-12 cycloalkyl.

### Claim 16 (depends on 15)

The method of claim 15, wherein R2 is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl.

### Claim 17 (depends on 15)

The method of claim 15, wherein R2 is substituted with one or more C1-4 alkyl, —OR4, or —C(═O)NR2, wherein each R4 is independently H or C1-6 alkyl, and each R is independently H or C1-4 alkyl.

### Claim 18 (depends on 15)

The method of claim 15, wherein R2 is substituted with one or more methyl, ethyl, propyl, isopropyl, —CH2OH, —CH(CH3)OH, —C(CH3)20H, —OH, —OCH3, —OCH2CH3, —C(═O)NH2, —C(═O)NHCH3, or —C(═O)N(CH3)2.

### Claim 19 (depends on 15)

The method of claim 15, wherein R2 is substituted with one or more methyl, —CH2OH, —C(CH3)20H, —OH, —OCH3, or —C(═O)NHCH3.

### Claim 20 (depends on 15)

The method of claim 15, wherein R2 is substituted or unsubstituted spiro[3.3]heptyl, or bicyclooctyl.

### Claim 21 (depends on 15)

The method of claim 15, wherein R2 is substituted with one or more C1-4 alkyl, —OR4, —C(═O)NR2, or triazolyl, wherein each R4 is independently H or C1-6 alkyl, and each R is independently H or C1-4 alkyl.

### Claim 22 (depends on 15)

The method of claim 15, wherein R2 is substituted with one or more methyl, triazolyl, —CH2OH, —C(CH3)20H, —OH, —OCH3, —C(═O)NH2, —C(═O)NHCH3, or —C(═O)N(CH3)2.

### Claim 23 (depends on 1)

The method of claim 1, wherein the compound at a concentration of 10 μM inhibits PKC-theta by at least about 50%.

### Claim 24 (depends on 1)

The method of claim 1, wherein the compound is
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the kinase is PKC-theta.

### Claim 26 (depends on 25)

The method of claim 25, wherein the compound is selective for PKC-theta over PKC-delta.

### Claim 27 (depends on 25)

The method of claim 25, wherein the compound is selective for PKC-theta over PKC-delta and PKC-eta.

### Claim 28 (depends on 26)

The method of claim 26, wherein the compound is at least 5-fold selective for PKC-theta over PKC-delta.

### Claim 29 (depends on 26)

The method of claim 26, wherein the compound is more than 100-fold selective for PKC-theta over PKC-delta.

### Claim 30

A method for the treatment or prevention of PKC-theta mediated disorder comprising administering to a subject in need thereof an effective amount of a compound, wherein the compound is
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof,
wherein the PKC-theta mediated disorder is graft-versus-host disease, organ transplant rejection, psoriasis, Duchenne muscular dystrophy, rheumatoid arthritis, insulin resistance, myasthenia gravis, multiple sclerosis, colitis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, Sjogren syndrome, asthma, or lupus.
